Hadar Ilan 4
4 · Silexion Therapeutics Corp · Filed Jun 8, 2026
Research Summary
AI-generated summary of this filing
Silexion (SLXN) CEO Hadar Ilan Receives 10,000-Share Award
What Happened Hadar Ilan, Chairman, CEO and a director of Silexion Therapeutics Corp (SLXN), was granted 10,000 fully vested restricted share units (RSUs) on June 4, 2026 that were immediately settled for 10,000 ordinary shares. The reported acquisition price is $0.00 (no cash paid). After this settlement, Ilan beneficially owns 16,547 ordinary shares in total (6,547 prior to the grant plus the 10,000 shares from the RSU settlement).
Key Details
- Transaction date: 2026-06-04; Form 4 filed: 2026-06-08 (filed within the standard 2-business-day window).
- Grant type/code: A (Award/Grant) — fully vested RSUs immediately settled for shares (per footnote).
- Shares acquired: 10,000 ordinary shares at $0.00 reported price; total reported shares owned after transaction: 16,547.
- Option holdings (adjusted for reverse split): 96 options to purchase 96 ordinary shares at an exercise price of $9,077.10 per share (adjustment due to 1-for-10 reverse split).
- Board approval: Grant was approved by the issuer’s board of directors (per footnote).
- Reverse split: A 1-for-10 reverse share split took effect May 28, 2026 and adjusted previously reported share and option counts/prices.
Context This was a compensation-related award (RSUs) settled immediately into shares for services as an officer, not an open-market purchase or sale. Such awards are routine forms of executive compensation and do not, by themselves, indicate a buy or sell signal. The option holdings were adjusted solely due to the issuer’s reverse split; the quoted exercise price reflects that adjustment.
Insider Transaction Report
- Award
Ordinary Shares
[F1][F2]2026-06-04+10,000→ 16,547 total
- 96
Stock Option (right to buy Ordinary Shares)
[F3][F4]Exercise: $9077.10From: 2024-08-15Exp: 2032-03-24→ Ordinary Shares (96 underlying)
Footnotes (4)
- [F1]The number of ordinary shares, par value $0.135 per share ("ordinary shares"), reported in this Form 4 reflects an adjustment relative to the Form 4 filed by the Reporting Person on February 23, 2026 due to the 1-for-10 reverse share split effected by the Issuer on May 28, 2026 (which caused the 65,471 ordinary shares, par value $0.0135, beneficially owned by the Reporting Person as reported in that Form 4 to become 6,547 ordinary shares, par value $0.135, prior to the grant reported in this Form 4).
- [F2]The transaction reported in this row consists of the grant to the Reporting Person by the Issuer of fully vested restricted share units (RSUs), which were immediately settled for underlying ordinary shares, in respect of the Reporting Person's services as an officer of the Issuer. The grant was approved by the Issuer's board of directors.
- [F3]There were no transactions effected in respect of the securities reported in this row, and the holdings in this row are being included for informational purposes only.
- [F4]The number of options to purchase ordinary shares and underlying ordinary shares, and the exercise price of the options, reported in this row have been adjusted to reflect the 1-for-10 reverse share split effected by the Issuer on May 28, 2026 (which caused the 956 options to purchase 956 ordinary shares, par value $0.0135, at an exercise price of $907.71 per share, beneficially owned by the Reporting Person as reported in that Form 4, to become 96 options to purchase 96 ordinary shares, par value $0.135, at an exercise price of $9,077.10 per share).